Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 4/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.44 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25699929 | 0.92 | MEN1 (0.50) | STSNR1H2KAT8KAT6AKAT5 | |
| SCHEMBL20656879 | 0.91 | GPR119 (0.50) | STSGPR119HPGDKDM4EPKM | |
| SCHEMBL31609166 | 0.87 | GPR119 (0.49) | STSGPR119NR1H2HPGDKDM4E | |
| SCHEMBL1318620 | 0.87 | GPR119 (0.46) | STSGPR119NR1H2KAT8KAT6A | |
| SCHEMBL1318622 | 0.87 | GPR119 (0.46) | STSGPR119NR1H2KAT8KAT6A | |
| SCHEMBL31609153 | 0.87 | GPR119 (0.49) | STSGPR119NR1H2HPGDKDM4E | |
| SCHEMBL20690682 | 0.87 | GPR119 (0.49) | STSGPR119NR1H2HPGDKDM4E | |
| SCHEMBL12136991 | 0.86 | NR1H2 (0.50) | GPR119NR1H2HPGDKDM4EPKM | |
| SCHEMBL14514518 | 0.86 | NR1H2 (0.50) | GPR119NR1H2HPGDKDM4EPKM | |
| SCHEMBL8426435 | 0.86 | NR1H2 (0.50) | GPR119NR1H2HPGDKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111132974-B | Sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20200361895-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-11-19 | — | — | US | disclosed |
| US-20200361895-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-11-19 | — | — | US | disclosed |
| CN-111132974-A | Novel sulfonamide carboxamide compounds | 英夫拉索姆有限公司 | 2020-05-08 | — | — | CN | disclosed |
| WO-2019034686-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361895-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | STS 218/4885GPR119 170/4885NR1H2 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.